High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation

Clinical Biochemistry

Volumn 48, Issue 16-17, 2015, Pages 1073-1078

  Cho, Hyo Jung ^a   Kim, Jai Keun ^a   Nam, Ji Sun ^b   Wang, Hee Jung ^a   Lee, Jei Hee ^a   Kim, Bong Wan ^a   Kim, Soon Sun ^a   Noh, Choong Kyun ^a   Shin, Sung Jae ^a   Lee, Kee Myung ^a   Cho, Sung Won ^a   Cheong, Jae Youn ^a  

^a Ajou University School of Medicine   (South Korea)

^b Ajou University Medical CentSuwon   (South Korea)

Author keywords

Hepatocellular carcinoma; MicroRNA 122; Prognosis; Radiofrequency ablation

Indexed keywords

MICRORNA 122; MICRORNA; MIRN122 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REAL TIME POLYMERASE CHAIN REACTION; SURGICAL PATIENT; SURVIVAL; THROMBOCYTE COUNT; BLOOD; CATHETER ABLATION; GENETICS; LIVER TUMOR; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK FACTOR; VIROLOGY;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

EID: 84947026401     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.06.019     Document Type: Article

References (33)

1. Jemal A., Ward E., Hao Y., Thun M. Trends in the leading causes of death in the united states, 1970-2002. JAMA 2005, 294:1255-1259.
2. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
3. Shiina S., Tateishi R., Arano T., Uchino K., Enooku K., Nakagawa H., et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am. J. Gastroenterol.\ 2012, 107:569-577.
4. Lee S.S., Shin H.S., Kim H.J., Lee S.J., Lee H.S., Hyun K.H., et al. Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J. Hepatol. 2012, 18:48-55.
5. Lee D.H., Lee J.M., Lee J.Y., Kim S.H., Han J.K., Choi B.I. Radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: long-term results and prognostic factors in 168 patients with cirrhosis. Cardiovasc. Intervent. Radiol. 2014, 37:705-715.
6. Cowan M.L., Vera J. Proteomics: advances in biomarker discovery. Expert Rev. Proteomics 2008, 5:21-23.
7. Ebert M.P., Korc M., Malfertheiner P., Rocken C. Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J. Proteome Res. 2006, 5:19-25.
8. Ebert M.S., Sharp P.A. Roles for micrornas in conferring robustness to biological processes. Cell 2012, 149:515-524.
9. Di Leva G., Garofalo M., Croce C.M. Micrornas in cancer. Annu. Rev. Pathol. 2014, 9:287.
10. Ghelani H.S., Rachchh M.A., Gokani R.H. Micrornas as newer therapeutic targets: a big hope from a tiny player. J. Pharmacol. Pharmacother. 2012, 3:217-227.
11. Fichtlscherer S., Zeiher A.M., Dimmeler S. Circulating micrornas biomarkers or mediators of cardiovascular diseases?. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2383-2390.
12. Redova M., Sana J., Slaby O. Circulating mirnas as new blood-based biomarkers for solid cancers. Future Oncol. 2013, 9:387-402.
13. Turchinovich A., Weiz L., Langheinz A., Burwinkel B. Characterization of extracellular circulating microrna. Nucleic Acids Res. 2011, 39:7223-7233.
14. Zhou J., Yu L., Gao X., Hu J., Wang J., Dai Z., et al. Plasma microrna panel to diagnose hepatitis b virus-related hepatocellular carcinoma. J. Clin. Oncol. 2011, 29:4781-4788.
15. Lakner A.M., Bonkovsky H.L., Schrum L.W. Micrornas: fad or future of liver disease. World J. Gastroenterol. 2011, 17:2536.
16. Wienholds E., Kloosterman W.P., Miska E., Alvarez-Saavedra E., Berezikov E., de Bruijn E., et al. Microrna expression in zebrafish embryonic development. Science 2005, 309:310-311.
17. Kutay H., Bai S., Datta J., Motiwala T., Pogribny I., Frankel W., et al. Downregulation of mir-122 in the rodent and human hepatocellular carcinomas. J. Cell. Biochem. 2006, 99:671-678.
18. Coulouarn C., Factor V.M., Andersen J.B., Durkin M.E., Thorgeirsson S.S. Loss of mir-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28:3526-3536.
19. Bihrer V., Friedrich-Rust M., Kronenberger B., Forestier N., Haupenthal J., Shi Y., et al. Serum mir-122 as a biomarker of necroinflammation in patients with chronic hepatitis c virus infection. Am. J. Gastroenterol. 2011, 106:1663-1669.
20. Network N. Nccn Clinical Practice Guidelines in Oncology; Hepatobiliary Cancers 2012, (Version).
21. Xu J., Wu C., Che X., Wang L., Yu D., Zhang T., et al. Circulating micrornas, mir-21, mir-122, and mir-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog. 2011, 50:136-142.
22. Tsai W.C., Hsu P.W., Lai T.C., Chau G.Y., Lin C.W., Chen C.M., et al. Microrna-122, a tumor suppressor microrna that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009, 49:1571-1582.
23. Coulouarn C., Factor V.M., Andersen J.B., Durkin M.E., Thorgeirsson S.S. Loss of mir-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28:3526-3536.
24. Hu J., Xu Y., Hao J., Wang S., Li C., Meng S. Mir-122 in hepatic function and liver diseases. PLoS One 2012, 3:364-371.
25. Qi P., Cheng S.Q., Wang H., Li N., Chen Y.F., Gao C.F. Serum micrornas as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis b virus infection. PLoS One 2011, 6:e28486.
26. Waidmann O., Bihrer V., Pleli T., Farnik H., Berger A., Zeuzem S., et al. Serum microrna-122 levels in different groups of patients with chronic hepatitis b virus infection. J. Viral Hepat. 2012, 19:e58-e65.
27. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., et al. Circulating micrornas, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4402-4407.
28. Cermelli S., Ruggieri A., Marrero J.A., Ioannou G.N., Beretta L. Circulating micrornas in patients with chronic hepatitis c and non-alcoholic fatty liver disease. PLoS One 2011, 6:e23937.
29. Crocetti L., de Baere T., Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc. Intervent. Radiol. 2010, 33:11-17.
30. N'Kontchou G., Mahamoudi A., Aout M., Ganne-Carrie N., Grando V., Coderc E., et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 western patients with cirrhosis. Hepatology 2009, 50:1475-1483.
31. Cabibbo G., Maida M., Genco C., Alessi N., Peralta M., Butera G., et al. Survival of patients with hepatocellular carcinoma (hcc) treated by percutaneous radio-frequency ablation (rfa) is affected by complete radiological response. PLoS One 2013, 8:e70016.
32. Xu Y., Bu X., Dai C., Shang C. High serum microrna-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients. Tumor Biol. 2015, 1-4.
33. Köberle V., Kronenberger B., Pleli T., Trojan J., Imelmann E., Peveling-Oberhag J., et al. Serum microrna-1 and microrna-122 are prognostic markers in patients with hepatocellular carcinoma. Eur. J. Cancer 2013, 49:3442-3449.